An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Latest Information Update: 28 May 2025
At a glance
- Drugs Atezolizumab (Primary) ; Mosunetuzumab (Primary) ; Mosunetuzumab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Genentech
Most Recent Events
- 21 May 2025 Planned End Date changed from 30 Sep 2025 to 1 Sep 2025.
- 18 Feb 2025 Planned End Date changed from 1 Sep 2025 to 30 Sep 2025.
- 10 Dec 2024 Results presented in the Roche Media Release.